StartUPDATES: New developments from healthcare startups
Check out new developments from Carrum Health, Sema4, Trulla, SpendMend, Monod Bio, and Evry Health.
Check out new developments from Carrum Health, Sema4, Trulla, SpendMend, Monod Bio, and Evry Health.
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
Read news from healthcare and life science companies including HealthMine, Zus Health, Sema4 and more.
The collaboration will build on AdventHealth's existing genomics and personalized health program, leveraging data to predict disease progression and response to treatments. Sema4's Centrellis data platform will be a core part of the new program.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Read about new developments from Blue Therapeutics, Docbot, Sema4, and Deep Lens.
The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.
Mount Sinai Health System's new spinout company, Sema4, will rely on genomic and clinical data to better diagnose, treat and prevent diseases.